News

Huntsman Cancer Institute at the University of Utah is one of the select sites in the United States to offer a new clinical trial for glioblastoma patients, called GBM AGILE. The clinical trial is using an approach that offers study participants multiple new glioblastoma drugs from different pharmaceutical companies.

Theresa Werner, MD, has been appointed senior director of clinical research at Huntsman Cancer Institute by Neli Ulrich, PhD, MS, executive director of the Comprehensive Cancer Center. Werner, a physician scientist and associate professor of medicine at the University of Utah.

Detection of skin cancer relies on visual examination, making it hard to reliably determine the skin cancer subtype and its extent of invasion into the skin. Researchers at Huntsman Cancer Institute have developed a potential new device to diagnose skin cancer using an electrical current.

Aria Vaishnavi, PhD, a postdoctoral fellow at Huntsman Cancer Institute is an awardee of the Lung Cancer Research Foundation 2021 Scientific Grant Program. Vaishnavi will be using this grant to better understand lung cancer caused by inhaled radon gas.

Martin McMahon, PhD, and his research group study the genetic mutations that contribute to lung cancer. About 30% of lung cancers can now be treated based on the disease’s specific genetics. McMahon is hopeful that each subset of lung cancer will soon have its own precision treatment.

Huntsman Cancer Institute physician and researcher Matthew Poppe, MD, received a National Cancer Institute grant to study side effects of different types of radiation—proton therapy and traditional radiation therapy—in the treatment of pediatric patients.

Douglas Sborov, MD, MS, discusses the work being done by the multiple myeloma and clinical trials programs at Huntsman Cancer Institute. He also shares why this work is so meaningful and how a Robin Williams character resonates with him in this latest Talks with Docs.

Huntsman Cancer Institute at the University of Utah announced the appointment of Howard Colman, MD, PhD, as the new co-leader of the Experimental Therapeutics Program. Colman is a physician-scientist at HCI, where he holds Jon M. Huntsman Presidential Professorship, and serves as a professor of neurosurgery at the U of U.